Vera Therapeutics, Inc. (VERA)
- Previous Close
40.75 - Open
40.88 - Bid 40.40 x 100
- Ask 40.79 x 100
- Day's Range
40.39 - 41.52 - 52 Week Range
7.10 - 50.78 - Volume
220,521 - Avg. Volume
1,011,291 - Market Cap (intraday)
2.227B - Beta (5Y Monthly) 1.11
- PE Ratio (TTM)
-- - EPS (TTM)
-2.01 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
50.00
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
veratx.comRecent News: VERA
Performance Overview: VERA
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VERA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VERA
Valuation Measures
Market Cap
2.23B
Enterprise Value
1.88B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
6.30
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-20.25%
Return on Equity (ttm)
-36.89%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-94.3M
Diluted EPS (ttm)
-2.01
Balance Sheet and Cash Flow
Total Cash (mrq)
403.66M
Total Debt/Equity (mrq)
15.06%
Levered Free Cash Flow (ttm)
-72.91M
Research Analysis: VERA
Company Insights: VERA
VERA does not have Company Insights